赢击长空
2023-11-17
吹牛逼,说好2期数据呢
Vaccitech rebrands as Barinthus, plans to present data at AASLD meeting
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":242523373674776,"tweetId":"242523373674776","gmtCreate":1700231026773,"gmtModify":1700231127716,"author":{"id":3550916429756056,"authorId":3550916429756056,"authorIdStr":"3550916429756056","name":"赢击长空","avatar":"https://static.tigerbbs.com/d67d618b2a23c914580657c77ce712c1","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":6,"crmLevelSwitch":0,"currentWearingBadge":{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.06.19","exceedPercentage":"93.56%","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>吹牛逼,说好2期数据呢</p></body></html>","htmlText":"<html><head></head><body><p>吹牛逼,说好2期数据呢</p></body></html>","text":"吹牛逼,说好2期数据呢","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/242523373674776","repostId":2381014751,"repostType":2,"repost":{"id":"2381014751","pubTimestamp":1699288734,"share":"https://www.laohu8.com/m/news/2381014751?lang=&edition=full","pubTime":"2023-11-07 00:38","market":"us","language":"en","title":"Vaccitech rebrands as Barinthus, plans to present data at AASLD meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2381014751","media":"seekingalpha","summary":"Vaccitech said that it has rebranded at Barinthus Biotherapeutics to reflect its expansion beyond developing vaccines. Barinthus shares will begin trading on Nasdaq under the symbol BRNS on Tuesday, Nov. 7. The company added that it plans to present Phase 2 data on its drug candidate VTP-300 in the treatment of patients with chronic hepatitis B at The American Association for the Study of Liver Diseases, or AASLD, to be held Nov. 10-14 in Boston. More on Vaccitech Vaccitech surges despite Morgan Stanley downgrade Seeking Alpha’s Quant Rating on Vaccitech Historical earnings data for Vaccitech Financial information for Vaccitech","content":"<html><body><p>Vaccitech (<span>NASDAQ:VACC</span>) said that it has rebranded at Barinthus Biotherapeutics (BRNS) to reflect its expansion beyond developing vaccines.</p> <p>Barinthus shares will begin trading on Nasdaq under the symbol BRNS on Tuesday, Nov. 7.</p> <p>The company added that it plans to<span> present Phase 2 data on its drug candidate VTP-300 in the treatment of patients with chronic hepatitis B at The American Association for the Study of Liver Diseases, or AASLD, to be held Nov. 10-14 in Boston. </span></p> <div> <h2>More on Vaccitech</h2> <ul> <li>Vaccitech surges despite Morgan Stanley downgrade</li> <li>Seeking Alpha’s Quant Rating on Vaccitech</li> <li>Historical earnings data for Vaccitech</li> <li>Financial information for Vaccitech</li> </ul> </div></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccitech rebrands as Barinthus, plans to present data at AASLD meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccitech rebrands as Barinthus, plans to present data at AASLD meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-11-07 00:38 GMT+8 <a href=https://seekingalpha.com/news/4031008-vaccitech-rebrands-as-barinthus-plans-to-present-data-at-aasld-meeting><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vaccitech (NASDAQ:VACC) said that it has rebranded at Barinthus Biotherapeutics (BRNS) to reflect its expansion beyond developing vaccines. Barinthus shares will begin trading on Nasdaq under the ...</p>\n\n<a href=\"https://seekingalpha.com/news/4031008-vaccitech-rebrands-as-barinthus-plans-to-present-data-at-aasld-meeting\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/977304138/image_977304138.jpg","relate_stocks":{"LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","QID":"纳指两倍做空ETF","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","LU0106831901.USD":"贝莱德世界金融基金A2","BK4588":"碎股","BRNS":"BARINTHUS BIOTHERAPEUTICS PLC ADR EACH REPR 1 ORD SH SPON",".IXIC":"NASDAQ Composite","QLD":"纳指两倍做多ETF","LU0971096721.USD":"富达环球金融服务 A","BK4581":"高盛持仓","BK4504":"桥水持仓","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","QQQ":"纳指100ETF","TQQQ":"纳指三倍做多ETF","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","BK4127":"投资银行业与经纪业","MS":"摩根士丹利","SQQQ":"纳指三倍做空ETF","BK4539":"次新股","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","BK4534":"瑞士信贷持仓","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","BK4585":"ETF&股票定投概念","BK4139":"生物科技","PSQ":"纳指反向ETF"},"source_url":"https://seekingalpha.com/news/4031008-vaccitech-rebrands-as-barinthus-plans-to-present-data-at-aasld-meeting","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2381014751","content_text":"Vaccitech (NASDAQ:VACC) said that it has rebranded at Barinthus Biotherapeutics (BRNS) to reflect its expansion beyond developing vaccines. Barinthus shares will begin trading on Nasdaq under the symbol BRNS on Tuesday, Nov. 7. The company added that it plans to present Phase 2 data on its drug candidate VTP-300 in the treatment of patients with chronic hepatitis B at The American Association for the Study of Liver Diseases, or AASLD, to be held Nov. 10-14 in Boston. More on Vaccitech Vaccitech surges despite Morgan Stanley downgrade Seeking Alpha’s Quant Rating on Vaccitech Historical earnings data for Vaccitech Financial information for Vaccitech","news_type":1},"isVote":1,"tweetType":1,"viewCount":449,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":20,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/242523373674776"}
精彩评论